Highest-materiality recent filing
Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026
Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.
Altimmune raises ~$211M in public offering to fund MASH Phase 3 trial
Offered 64.25M common shares at $3.00/share and pre-funded warrants for up to 10.75M shares.
Altimmune ends FY2025 with $274M cash; FDA breakthrough for MASH; Phase 3 planned 2026
Cash, cash equivalents and short-term investments: $274M at Dec 31, 2025; ~$340M after $75M offering and $8M ATM in Jan 2026.
Altimmune raises ~$75M in registered direct offering of common stock and pre-funded warrants
Issued 12.4M shares and pre-funded warrants for 4.6M shares at $4.40/share; gross proceeds ~$75M.
Altimmune reports positive 48-week IMPACT data; FDA agrees on Phase 3 path for pemvidutide
Pemvidutide 1.8 mg reduced ELF by -0.58 (p<0.0001) and LSM by -3.97 (p<0.001) vs placebo at 48 weeks.
Altimmune CEO Vipin Garg to step down Jan 1, 2026; Chairman Jerome Durso named successor
Vipin Garg transitions from President/CEO to advisor through June 30, 2026; remains on board until Jan 31, 2026.
Altimmune Q3 net loss $19M ($0.21/sh); cash $210.8M; debt facility upsized to $125M
Cash and investments $210.8M, up 60% from Dec 2024; net loss $19.0M vs $22.8M year ago.
Entered November 2025 Agreement with Leerink Partners for ATM offering of up to $200M common stock.
Cash and investments $183.1M (up 39% from Dec 2024); net loss $22.1M ($0.27/sh) vs $24.6M ($0.35) Q2 2024.
MASH resolution without worsening fibrosis: 59.1% (1.2mg) and 52.1% (1.8mg) vs 19.1% placebo (p<0.0001).
Altimmune gets $100M Hercules facility, Q1 cash $150M, MASH data expected Q2 2025
Up to $100M term loan from Hercules; $15M funded at closing, $25M more in 2025 subject to milestones.
Phase 2 AUD trial for pemvidutide targeting moderate to severe AUD; ~100 subjects, 24 weeks, endpoints include heavy drinking days.
Altimmune posts Q4 net loss $23.2M; CMO to retire; pemvidutide MASH data on track
Net loss Q4 2024 $23.2M ($0.33/share) vs $31.6M in Q4 2023 (incl $12.4M impairment); FY2024 net loss $95.1M ($1.34/share).
Altimmune appoints former Dexcom CCO Teri Lawver and ex-Intercept CEO Jerry Durso to board
Board expanded by two to ten; Lawver and Durso appointed effective Feb 24, 2025.
Altimmune reports pemvidutide Phase 1b MASLD data: LFC reduced up to 68.5%
Pemvidutide reduced liver fat content (LFC) by up to 68.5% from baseline over 12 weeks in 94 MASLD patients.
Altimmune names Greg Weaver CFO, with $475k salary and 225k option grant
Mr. Weaver appointed CFO effective Nov 11, 2024; previously CFO at atai Life Sciences.
Altimmune Q3 net loss $22.8M; IMPACT enrollment done, FDA obesity plan set
Net loss of $22.8M ($0.32/share) vs $20.7M ($0.39/share) in Q3 2023.
Altimmune Q2 net loss $24.6M; pemvidutide MASH Phase 2b topline due Q1 2025
Cash, cash equivalents and short-term investments totaled $164.9M as of June 30, 2024.
Altimmune CFO Richard Eisenstadt dies unexpectedly; Andrew Shutterly named acting CFO
Richard Eisenstadt, CFO, passed away unexpectedly on June 24, 2024.
Altimmune reports Q1 2024 net loss $24.4M; cash $182.1M; pemvidutide milestones on track
Net loss $24.4M ($0.34/share) vs $20.1M ($0.40) in Q1 2023; R&D expense $21.5M on pemvidutide and HepTcell winddown.
Net loss $31.6M ($0.54/share) for Q4 2023, including $12.4M impairment for discontinued HepTcell program.
Altimmune reports Phase 2 obesity trial: 15.6% mean weight loss with pemvidutide 2.4 mg at Week 48
Mean weight loss of 15.6% on 2.4 mg dose vs 2.2% placebo; near-linear trajectory at end of treatment.
Altimmune Q3 net loss $0.39/sh; cash $140.8M; obesity trial readout Q4 2023
Net loss $20.7M ($0.39/sh) vs $23.5M ($0.48) in Q3 2022.
Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24; p < 0.001 vs placebo.
Net loss for Q4 2022 was $21.7M ($0.43 per share) vs $23.9M ($0.57) in Q4 2021; revenue negligible.
At 1.8 mg dose, mean relative liver fat reduction 75.2%; 53.8% achieved normalization (≤5% LFC).
Altimmune Q3 net loss $23.5M, cash $201.9M; pemvidutide NAFLD data mid-Dec, obesity interim Q1 2023
Net loss of $23.5M ($0.48 per share) vs $33.5M loss YoY; revenue minimal at ~$0.
Altimmune Phase 1b pemvidutide: 68.5% liver fat reduction, 4.9% weight loss at 12 weeks
At 1.8 mg dose, relative liver fat reduction of 68.5%; 94.4% of subjects achieved ≥30% reduction.
Altimmune Q2 net loss $20.1M ($0.42/share); cash $184.8M; pemvidutide Phase 1b data mid-Sept
Net loss of $20.1M ($0.42 per share) for Q2 2022 vs $24.8M ($0.60) in Q2 2021, which included $8.1M impairment.
Altimmune Q1 net loss $19.4M ($0.44/share); cash $180.0M; key pemvidutide data readouts Q3/Q4 2022
Net loss of $19.4M ($0.44 per share) vs $14.9M ($0.38) in Q1 2021; R&D expense $15.1M.
Altimmune Q3 net loss $33.5M; pemvidutide shows liver fat reduction to undetectable levels
Net loss of $33.5M ($0.81 per share) for Q3 2021, up from $17.8M in Q3 2020.
Altimmune Phase 1 pemvidutide shows 10.3% mean weight loss at 1.8 mg; NASH IND cleared
Mean weight loss of 10.3% at 1.8 mg dose vs. 1.6% placebo; 100% of subjects lost ≥5%.
Altimmune Q2 net loss $24.8M; ALT-801 Phase 1 data expected Sept 2021
Q2 net loss $24.8M ($0.60/shr) vs $16.8M ($0.94/shr) prior year; revenue $0.1M down from $0.7M.
On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.
On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.
On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.
On November 11, 2024, Altimmune, Inc. (the “Company”) issued a press release announcing the decision of the Company’s Board of Directors (the “Board”) to appoint Mr. Gregory Weaver as the Company’s Chief Financial Officer (“CFO”), effective November 11, 2024.
On August 13, 2024, David J. Drutz, M.D. notified the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) that he has decided not to stand for re-election to the Board at the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).
following the unexpected death of Richard Eisenstadt, the Company’s Chief Financial Officer.
appointed Andrew Shutterly as acting Chief Financial Officer
appointed Catherine Sohn, Pharm.D. as a director of the Company’s Board, effective March 23, 2023.
William Brown, the Chief Financial Officer, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021.
the Company issued a press release announcing the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s Chief Financial Officer (“CFO”), effective December 31, 2021.
Max materiality 0.90 · Median 0.60 · Most common event other_material